OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell Carcinoma

September 22nd 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma

Dr. Steinberg on BCG Progression in Non-Muscle Invasive Bladder Cancer

September 22nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses bacillus Calmette-Guérin (BCG) progression in non-muscle invasive bladder cancer (NMIBC).

Dr. Rule on Rituximab Biosimilar Use in the UK

September 22nd 2018

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the use of biosimilars in the United Kingdom for the treatment of cancer.

Dr. Konstantinopoulos Discusses PARP Plus Immunotherapy

September 22nd 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the combination of PARP inhibitors and immunotherapy.

Dr. Cohen on the Evolution of Antibodies in Lymphoma

September 22nd 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the evolution of antibodies for the treatment of lymphoma.

Dr. Primrose on Adjuvant Capecitabine For Biliary Tract Cancer

September 21st 2018

John Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.

Dr. Gentzler on Combination Therapies in NSCLC

September 21st 2018

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses combination therapies in non–small cell lung cancer (NSCLC).

Dr. Graff on Novel Therapies in Metastatic Breast Cancer

September 21st 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.

Dr. Singh on Treatment for Patients With Uterine Leiomyosarcoma

September 21st 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses treatment for patients with uterine leiomyosarcoma.

Dr. Madduri Discusses Checkpoint Inhibitors in Myeloma

September 20th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the use of checkpoint inhibitors in multiple myeloma.

Dr. Shiller on Next-Generation Sequencing in GI Cancers

September 20th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing in gastrointestinal malignancies.

Dr. Haigentz on the Impact of Immunotherapy in Head and Neck Cancer

September 20th 2018

Missak Haigentz, MD, chief of Hematology and Oncology at Morristown Medical Center, medical director of Atlantic Hematology and Oncology for Atlantic Medical Group at the Carol G. Simon Cancer Center, discusses the impact that immunotherapy has had on the treatment of patients with head and neck cancer.

Dr. Sapisochin on Neoadjuvant Treatment for HCC

September 20th 2018

Gonzalo Sapisochin, MD, assistant professor of surgery, University of Toronto, discusses neoadjuvant treatment for patients with hepatocellular carcinoma.

Dr. Kalinsky on CNS Involvement in HER2+ Breast Cancer

September 20th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.

Dr. Shah on Treatment of Patients with p53-Mutated MCL

September 20th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the treatment of patients with p53-mutated mantle cell lymphoma.

Dr. Bunn on the Treatment of Early-Stage Lung Cancer

September 20th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the treatment of patients with early-stage non–small cell lung cancer.

Dr. Konecny on the Value of PARP Inhibitors in Ovarian Cancer

September 19th 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses studies that demonstrate the value of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Sonpavde on Remaining Questions With Immunotherapy in Bladder Cancer

September 19th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer.

Dr. Ali on Adjuvant Studies With Biosimilars in Oncology

September 19th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses adjuvant studies with biosimilars in oncology.

Dr. Eng Discusses the ADORE Trial in Rectal Cancer

September 19th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.